Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Parulekar

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
International Journal of Radiation Oncology, Biology, Physics|September 23, 2008
Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3)Georg A Bjarnason, Robert G Mackenzie, Abdenour Nabid, et al.
International Journal of Radiation Oncology, Biology, Physics|May 7, 2023
Salvage Radiation Therapy After Radical Prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT TrialPeter Meidahl Petersen, Adrian D Cook, Matthew R Sydes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trialsEdward L Korn, Ping-Yu Liu, Sandra J Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2023
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Lancet (London, England)|November 8, 2011
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trialPadraig Warde, Malcolm Mason, Keyue Ding, et al.
European Urology|May 22, 2024
Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized TrialsPraful Ravi, Wanling Xie, Marc Buyse, et al.
Journal of the National Cancer Institute|February 2, 2021
The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32Isabel Pimentel, Bingshu E Chen, Ana Elisa Lohmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With RadiationWanling Xie, Meredith M Regan, Marc Buyse, et al.
Future Oncology (London, England)|January 17, 2025
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)Ciara Conduit, Andrisha-Jade Inderjeeth, Raymond Allen, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
International Journal of Radiation Oncology, Biology, Physics|September 23, 2008
Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3)Georg A Bjarnason, Robert G Mackenzie, Abdenour Nabid, et al.
International Journal of Radiation Oncology, Biology, Physics|May 7, 2023
Salvage Radiation Therapy After Radical Prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT TrialPeter Meidahl Petersen, Adrian D Cook, Matthew R Sydes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trialsEdward L Korn, Ping-Yu Liu, Sandra J Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2023
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Lancet (London, England)|November 8, 2011
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trialPadraig Warde, Malcolm Mason, Keyue Ding, et al.
European Urology|May 22, 2024
Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized TrialsPraful Ravi, Wanling Xie, Marc Buyse, et al.
Journal of the National Cancer Institute|February 2, 2021
The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32Isabel Pimentel, Bingshu E Chen, Ana Elisa Lohmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With RadiationWanling Xie, Meredith M Regan, Marc Buyse, et al.
Future Oncology (London, England)|January 17, 2025
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)Ciara Conduit, Andrisha-Jade Inderjeeth, Raymond Allen, et al.
Pageof 3